Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa ...Middle East

After 3 years of follow-up in AMPECT trial, confirmed clinically meaningful overall response rate, including multiple patients with complete responses Demonstrated 40 months median duration of response and median survival >53 months Historically, median survival has ranged from 16 to 29...

Read More Details
Finally We wish PressBee provided you with enough information of ( Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa )

Also on site :

• 'Hissing door mid-air': AI flight to Hong Kong spooks flyers; crew use napkins to 'fix' issue
• Israel says it killed a commander of Iranian force that oversees proxy militias.
• Shoppers Are Racing to Walmart To Buy an 'Impressive' 834-Piece LEGO 'Star Wars' Set